Abstract
This study aims to evaluate cerebrospinal fluid (CSF) flow dynamics within ventricles, and the subarachnoid space (SAS) using the velocity selective spin labeling (VSSL) MRI method with Fourier-transform-based velocity selective inversion preparation. The study included healthy volunteers who underwent MRI scanning with specific VSSL parameters optimized for CSF flow quantification. The VSSL sequence was calibrated against phase-contrast MRI (PC-MRI) to ensure accurate flow velocity measurements. The CSF flow patterns observed in the ventricles were consistent with those obtained using 3D amplified MRI and other advanced MRI techniques, verifying the reliability of the VSSL method. The VSSL method successfully measured CSF flow in the SAS along major arteries, including the middle cerebral artery (MCA), anterior cerebral artery (ACA), and posterior cerebral artery (PCA), with an average flow velocity of 0.339 ± 0.117 cm/s. The diffusion component was well suppressed by flow-compensated gradients, enabling comprehensive mapping of the rapid CSF flow pattern in the SAS system and ventricles. The flow pattern in the SAS system closely resembles the recently discovered perivascular subarachnoid space (PVSAS) system. CSF flow around the MCA, PCA, and ACA arteries in the SAS exhibited a weak orientation dependency. CSF flow in the ventricles was also measured, with an average flow velocity of 0.309 ± 0.116 cm/s, and the highest velocity observed along the superior-inferior direction. This study underscores the potential of VSSL MRI as a non-invasive tool for investigating CSF dynamics in both SAS and ventricles.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Grant support from NIH: P41EB031771, R01HL149742, R01AG080104 and R21AG074978.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Johns Hopkins Medicine Institutional Review Board (IRB), and all participants have provided their informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Grant support from NIH: P41EB031771, R01HL149742, R01AG080104 and R21AG074978.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.